American Well (NYSE:AMWL) Price Target Raised to $12.00

American Well (NYSE:AMWL - Get Free Report) had its price objective lifted by equities researchers at Truist Financial from $10.00 to $12.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has a "hold" rating on the stock. Truist Financial's target price would suggest a potential upside of 1.48% from the stock's previous close.

A number of other research firms have also commented on AMWL. Stifel Nicolaus lifted their target price on shares of American Well from $9.00 to $10.00 and gave the stock a "hold" rating in a report on Thursday, February 13th. Needham & Company LLC reaffirmed a "hold" rating on shares of American Well in a research note on Thursday, February 13th. Morgan Stanley dropped their price objective on American Well from $20.00 to $10.50 and set an "equal weight" rating for the company in a report on Tuesday, December 17th. Finally, Wells Fargo & Company upgraded American Well from an "equal weight" rating to an "overweight" rating and set a $15.00 target price on the stock in a report on Monday, January 13th. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $11.90.

American Well Trading Down 2.8 %

Shares of AMWL traded down $0.34 during trading hours on Friday, hitting $11.83. 178,430 shares of the stock traded hands, compared to its average volume of 72,795. The business has a fifty day moving average of $9.41 and a 200-day moving average of $9.19. The firm has a market capitalization of $181.16 million, a PE ratio of -0.81 and a beta of 1.18. American Well has a 1-year low of $5.00 and a 1-year high of $26.40.

American Well (NYSE:AMWL - Get Free Report) last released its earnings results on Wednesday, February 12th. The company reported ($2.77) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.04) by $0.27. American Well had a negative net margin of 84.27% and a negative return on equity of 52.49%. As a group, equities research analysts expect that American Well will post -13.38 earnings per share for the current fiscal year.

Institutional Investors Weigh In On American Well

Several large investors have recently modified their holdings of AMWL. Senvest Management LLC lifted its holdings in shares of American Well by 3.9% during the 4th quarter. Senvest Management LLC now owns 1,300,611 shares of the company's stock valued at $9,429,000 after purchasing an additional 48,800 shares in the last quarter. 4D Advisors LLC acquired a new stake in American Well during the 4th quarter worth approximately $1,088,000. Geode Capital Management LLC lifted its stake in American Well by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 147,925 shares of the company's stock valued at $1,073,000 after buying an additional 922 shares in the last quarter. Bridgeway Capital Management LLC boosted its holdings in shares of American Well by 39.4% in the fourth quarter. Bridgeway Capital Management LLC now owns 96,741 shares of the company's stock valued at $701,000 after buying an additional 27,343 shares during the period. Finally, Takeda Pharmaceutical Co. Ltd. bought a new stake in shares of American Well during the fourth quarter worth $564,000. 56.05% of the stock is currently owned by institutional investors.

American Well Company Profile

American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Converge, a cloud-based platform that enables health providers, payers, and innovators to provide in-person, virtual and automated care; and delivers virtual primary care, post-discharge follow-up, chronic condition management, virtual nursing, e-sitting, on-demand and scheduled virtual visits, specialty consults, automated care, and behavioral health, as well as specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care to patients and members.